Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Viatris
VTRS
Viatris
Regulatory Burdens Will Squeeze Margins Though Pipeline Will Offer Little
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
22 Aug 25
Updated
22 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$8.00
33.1% overvalued
intrinsic discount
22 Aug
US$10.65
Loading
1Y
-9.4%
7D
0.2%
Author's Valuation
US$8.0
33.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$8.0
33.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-3b
17b
2014
2017
2020
2023
2025
2026
2028
Revenue US$14.3b
Earnings US$92.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
1.15%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.13%
Calculation
US$92.43m
Earnings '28
x
115.52x
PE Ratio '28
=
US$10.68b
Market Cap '28
US$10.68b
Market Cap '28
/
1.09b
No. shares '28
=
US$9.83
Share Price '28
US$9.83
Share Price '28
Discounted to 2025 @ 7.12% p.a.
=
US$8.00
Fair Value '25
